SCHEMBL439796

SCHEMBL439796

Nc1c(Br)cnc2ccccc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.50
ALDH1A1 P00352 2/20 0.50
GLA P06280 2/20 0.50
HPGD P15428 2/20 0.50
CASP1 P29466 2/20 0.50
CASP7 P55210 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
HSD17B10 Q99714 2/20 0.50
CHRM2 P08172 1/20 0.50
ADRA2A P08913 1/20 0.50
ADORA3 P0DMS8 1/20 0.50
CHRM1 P11229 1/20 0.50
NQO2 P16083 1/20 0.50
MAOA P21397 1/20 0.50
DRD1 P21728 1/20 0.50
ACHE P22303 1/20 0.50
SLC6A2 P23975 1/20 0.50
ADRA1A P35348 1/20 0.50
OPRM1 P35372 1/20 0.50
KCNH2 Q12809 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL5990892 0.98 KDM4E (0.48) KDM4EALDH1A1GLAHPGDCASP1
SCHEMBL28890935 0.78 GPR3 (0.50) KDM4ESMN1; SMN2ADORA3RAB9AMAPT
SCHEMBL203711 0.78 LMNA (0.55) KDM4EALDH1A1GLAHPGDCASP1
SCHEMBL29742219 0.78 LMNA (0.55) KDM4EALDH1A1GLAHPGDCASP1
Ammonia Solution, Strong SCHEMBL6035045 0.77 LMNA (0.53) KDM4EALDH1A1GLAHPGDCASP1
SCHEMBL438613 0.76 BCHE (0.45) ALDH1A1SMN1; SMN2ACHELMNAMAPT
SCHEMBL437952 0.76 ACHE (0.45) ACHEHTTKMT2ACYP1A2
SCHEMBL23234986 0.75 KDM4E (0.50) KDM4EALDH1A1GLAHPGDCASP1
SCHEMBL437696 0.75 KDM4E (0.50) KDM4EALDH1A1GLAHPGDCASP1
SCHEMBL29076087 0.75 ERN1 (0.55) KDM4EALDH1A1GLAHPGDCASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105461623-A Synthetic method of 4-amino-6-nitro-3-bromoquinoline UNIV JIANGSU TECHNOLOGY 2016-04-06 CN claimed
US-20120065166-A1 Bone Modulators And Methods Therewith ESPINA VIRGINIA (US) 2012-03-15 US claimed
US-20250257035-A1 1,4-Substituted Piperidine Derivatives CEPHALON LLC 2025-08-14 US disclosed
US-12098130-B2 1,4-substituted piperidine derivatives 89BIO LTD (IL) 2024-09-24 US disclosed
US-20230391723-A1 1,4-Substituted Piperidine Derivatives CEPHALON LLC 2023-12-07 US disclosed
US-11702388-B2 1,4-substituted piperidine derivatives 89BIO LTD (IL) 2023-07-18 US disclosed
US-20210230116-A1 1,4-Substituted Piperidine Derivatives CEPHALON LLC 2021-07-29 US disclosed
CN-107847765-B 1, 4-substituted piperidine derivatives 89生物有限公司 2021-05-04 CN disclosed
US-10851057-B2 1,4-substituted piperidine derivatives 89BIO LTD (IL) 2020-12-01 US disclosed
EP-3310441-B1 1, 4-SUBSTITUTED PIPERIDINE DERIVATIVES 89BIO LTD (IL) 2020-07-29 EP disclosed
US-20190152913-A1 1,4-SUBSTITUTED PIPERIDINE DERIVATIVES CEPHALON LLC 2019-05-23 US disclosed
CN-101346141-A Quinoline derivatives useful in the treatment of MGLUR5 receptor-mediated disorders RICHTER GEDEON NYRT (HU) 2009-01-14 CN disclosed
EP-1962849-A1 QUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF MGLUR5 RECEPTOR-MEDIATED DISORDERS Richter Gedeon NYRT (HU) 2008-09-03 EP disclosed
WO-2007072093-A1 QUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF MGLUR5 RECEPTOR-MEDIATED DISORDERS RICHTER GEDEON NYRT. (HU) 2007-06-28 WO disclosed
US-20060030565-A1 Amide derivatives and nociceptin antagonists JAPAN TOBACCO INC. 2006-02-09 US disclosed
US-6903094-B2 Amide derivatives and nociceptin antagonists JAPAN TABACCO, INC. (JP) 2005-06-07 US disclosed
US-20030055087-A1 Amide derivatives and nociceptin antagonists JAPAN TOBACCO INC. 2003-03-20 US disclosed
US-6410561-B1 ANALGESICS JAPAN TOBACCO INC. (JP) 2002-06-25 US disclosed
CN-1301154-A Amide derivatives and nociceptin antagonists JAPAN TOBACCO INC (JP) 2001-06-27 CN disclosed
EP-1072263-A1 AMIDE DERIVATIVES AND NOCICEPTIN ANTAGONISTS JAPAN TOBACCO INC. (JP) 2001-01-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250257035-A1 1,4-Substituted Piperidine Derivatives FASN, CES1, CPT1A KDM4E 1054/4885ALDH1A1 110/4885GLA 3087/4885
US-20190152913-A1 1,4-SUBSTITUTED PIPERIDINE DERIVATIVES FASN, CES1, CPT1A KDM4E 1054/4885ALDH1A1 110/4885GLA 3087/4885
US-20030055087-A1 Amide derivatives and nociceptin antagonists OPRL1, OPRD1, OPRK1 KDM4E 2398/4885ALDH1A1 2407/4885GLA 4550/4885
US-20230391723-A1 1,4-Substituted Piperidine Derivatives FASN, CES1, CPT1A KDM4E 1054/4885ALDH1A1 110/4885GLA 3087/4885
US-20210230116-A1 1,4-Substituted Piperidine Derivatives FASN, CES1, CPT1A KDM4E 1054/4885ALDH1A1 110/4885GLA 3087/4885
US-11702388-B2 1,4-substituted piperidine derivatives FASN, CES1, CPT1A KDM4E 1054/4885ALDH1A1 110/4885GLA 3087/4885
US-12098130-B2 1,4-substituted piperidine derivatives FASN, CES1, CPT1A KDM4E 1054/4885ALDH1A1 110/4885GLA 3087/4885
US-10851057-B2 1,4-substituted piperidine derivatives FASN, CES1, CPT1A KDM4E 1054/4885ALDH1A1 110/4885GLA 3087/4885
US-20060030565-A1 Amide derivatives and nociceptin antagonists OPRL1, OPRD1, OPRM1 KDM4E 2650/4885ALDH1A1 2404/4885GLA 4524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.